GLSI
Greenwich LifeSciences, Inc. [GLSI] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
GLSI Stock Summary
Top 10 Correlated ETFs
GLSI
Top 10 Correlated Stocks
GLSI
In the News
GLSI Financial details
Company Rating
-
Market Cap
201.07M
Income
-8.67M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
22 May 2024
P/E
-15.22
Forward P/E
-
PEG
-1.57
P/S
-
P/B
14.91
P/C
-
P/FCF
-20.32
Quick Ratio
30.76
Current Ratio
30.76
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.69
EPS next Y
-
EPS next Q
-
EPS this Y
68.57%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
46.15%
-
-
-
-
SMA20
-20.5%
SMA50
-28.28%
SMA100
-29.33%
Inst Own
-
Inst Trans
-
ROA
-95%
ROE
-78%
ROC
-1.06%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.58-21.44
52W High
-55.52%
52W Low
+33.43%
RSI
42.08
Rel Volume
1.93
Avg Volume
49.77K
Volume
96.2K
Perf Week
-0.95%
Perf Month
-22.81%
Perf Quarter
-31.27%
Perf Half Y
-30.25%
-
-
-
-
Beta
3.191
-
-
Volatility
0.32%, 1.12%
Prev Close
4.36%
Price
9.34
Change
5.06%
Company Profile
- Volume Average 49.77K
- Market Capitalization 201.07M
- Employee 3
- CEO Mr. Snehal S. Patel
- Headquarters Stafford,TX,US
- IPO Date 2020-09-25
-
Website
https://greenwichlifesciences.com 
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
